Eli Lilly announced that its Taltz and Zepbound treatment helped patients with psoriatic arthritis over a year.

Nov 11, 2026, 1:13 PM ETTrialRead the original at Benzinga

Good for LLY

At 52 weeks, 39.2% on the combination met the joint-disease and weight-loss goal, versus 1.7% on Taltz alone. The open-label design makes results less certain, but the gap favors Lilly.

LLY · Eli Lilly and Co.

AI read · Good for LLY

The AI's read

The results add evidence that the two medicines can help patients with psoriatic arthritis and weight loss. The study was open-label, so its results are less certain than a blinded comparison. Still, the reported differences at 52 weeks support a favorable read for Lilly.

Get alerts for LLY

Follow Eli Lilly and Co. (LLY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LLY

Free on the App Store and Google Play, or on the web.